Apotex Revolutionizes Osteoporosis Care in Canada with New Denosumab Biosimilar Approval

Source link : https://www.mondialnews.com/2026/04/07/apotex-revolutionizes-osteoporosis-care-in-canada-with-new-denosumab-biosimilar-approval/

Apotex Inc. has taken a significant step forward in enhancing osteoporosis treatment options across Canada with Health Canada’s official approval of DENOZA, a denosumab biosimilar. This development promises to improve patient access to effective bone loss therapies by offering a more affordable alternative to existing biologic treatments. As osteoporosis continues to affect millions of Canadians, Apotex’s latest addition aims to make impactful strides in managing this chronic condition and supporting better health outcomes nationwide.

Apotex Receives Health Canada Approval for DENOZA Biosimilar Enhancing Osteoporosis Treatment Options

Apotex has achieved a significant milestone in expanding treatment options for osteoporosis patients across Canada with the Health Canada approval of DENOZA, a biosimilar to denosumab. This approval marks a pivotal moment in the Canadian pharmaceutical landscape, offering healthcare providers and patients a more accessible and cost-effective alternative to the innovative biologic medicine. DENOZA is expected to enhance patient outcomes by maintaining the rigorous efficacy and safety profiles established by the reference biologic, thereby supporting bone health and reducing fracture risks associated with osteoporosis.

Key features of DENOZA include:

• Therapeutic equivalence to the branded denosumab product
• Potential for reduced treatment costs, increasing affordability
• Support for both healthcare providers and patients through Apotex’s…

—-

Author : Olivia Williams

Publish date : 2026-04-07 14:24:00

Copyright for syndicated content belongs to the linked Source.

—-

1 – 2 – 3 – 4 – 5 – 6 – 7 – 8